Search hospitals > Texas > Austin

University of Texas at Austin

Claim this profile
Austin, Texas 78712
Global Leader in Cancer
Global Leader in Depression
Conducts research for Breast Cancer
Conducts research for Post-Traumatic Stress Disorder
Conducts research for Anxiety Disorders
158 reported clinical trials
31 medical researchers
Photo of University of Texas at Austin in AustinPhoto of University of Texas at Austin in AustinPhoto of University of Texas at Austin in Austin

Summary

University of Texas at Austin is a medical facility located in Austin, Texas. This center is recognized for care of Cancer, Depression, Breast Cancer, Post-Traumatic Stress Disorder, Anxiety Disorders and other specialties. University of Texas at Austin is involved with conducting 158 clinical trials across 386 conditions. There are 31 research doctors associated with this hospital, such as Om N. Pandey, Hirofumi Tanaka, PhD, Boone W. Goodgame, and Anna Capasso, MD.

Area of expertise

1Cancer
Global Leader
University of Texas at Austin has run 30 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage II
HER2 positive
2Depression
Global Leader
University of Texas at Austin has run 22 trials for Depression.

Top PIs

Clinical Trials running at University of Texas at Austin

Non-Small Cell Lung Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Post-Traumatic Stress Disorder
Depression
Cancer
Multiple Sclerosis
Gastroesophageal Junction Adenocarcinoma
Diabetic Neuropathy
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

RMC-6236

for Cancer

This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
Recruiting1 award Phase 14 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Texas at Austin?
University of Texas at Austin is a medical facility located in Austin, Texas. This center is recognized for care of Cancer, Depression, Breast Cancer, Post-Traumatic Stress Disorder, Anxiety Disorders and other specialties. University of Texas at Austin is involved with conducting 158 clinical trials across 386 conditions. There are 31 research doctors associated with this hospital, such as Om N. Pandey, Hirofumi Tanaka, PhD, Boone W. Goodgame, and Anna Capasso, MD.